Krystal Biotech, Inc. announced selected preliminary unaudited 2025 financial results.
Preliminary unaudited fourth quarter and full year 2025 VYJUVEK net product revenue was between $106 million and $107 million.
The Company outlined its strategic vision to drive the next stage of growth in the rare disease business.
Financial Results
Preliminary unaudited net product revenue for VYJUVEK in Q4 2025: $106-107 million. Full year 2025 VYJUVEK net revenue: $388-389 million.
Strategic Vision
Focus on rare disease pipeline development with programs like KB803, KB801, KB407, and KB111. Vision to have at least four marketed rare disease medicines by 2030.
Clinical Development
Increased enrollment target for KB801 study. Top-line data from the study expected in 2026.
- Krystal Biotech had a successful year in 2025 with the launch of VYJUVEK in Europe and Japan.
- The Company's strategic vision targets expedited development of rare disease treatments with a focus on key programs.
- Krystal Biotech aims to have a significant impact in rare disease market with multiple potential blockbuster launches in the next four years.
With a strong financial performance in 2025 and a robust pipeline for rare diseases, Krystal Biotech is poised for sustained growth and impact in the biotech industry.